Discover 1,272 paid clinical trials in Mesa, Arizona. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Filter
2
Filter results
Results: 1,272
Sonocloud-9 in Association With Carboplatin Versus Standard-of-Care Chemotherapies (CCNU or TMZ) in Recurrent GBM
for
Glioblastoma, Recurrent Glioblastoma, GBM
Location: Phoenix AZ, Salt Lake City UT, Aurora CO,
Sponsor: CarThera
Sex: All
Age: 18+
Code: NCT05902169
Phase3, Recruiting
A US Non-interventional, Effectiveness and Safety Study of Patients Treated With SKYTROFA
for
Growth Hormone Deficiency
Location: Phoenix AZ, Las Vegas NV, El Paso TX, Orange CA,
A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
for
Solid Tumors
Location: Phoenix AZ, Santa Monica CA, Palo Alto CA, Houston TX,
Sponsor: Incyte Corporation
Sex: All
Age: 18+
Code: NCT06179160
Phase1, Recruiting
A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations
for
NSCLC (Advanced Non-small Cell Lung Cancer)
Location: Phoenix AZ, La Jolla CA, Irvine CA, Sacramento CA,
Sponsor: BlossomHill Therapeutics
Sex: All
Age: 18+
Code: NCT06706076
Phase1, Phase2, Recruiting
Comparing Retreatment of 177Lu-DOTATATE PRRT Versus the Usual Treatment in Patients With Metastatic Unresectable Gastroenteropancreatic Neuroendocrine Tumors, NET RETREAT Trial
for
Metastatic Digestive System Neuroendocrine Tumor G1,
Location: Phoenix AZ, Tucson AZ, Albuquerque NM,
Sponsor: National Cancer Institute (NCI)
Sex: All
Age: 18+
Code: NCT05773274
Phase2, Recruiting
Interested in new trials?
Get alerts for new trials in your area by subscribing now
Trial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder Cancer
for
Intermediate Risk Non-Muscle Invasive Bladder Cancer
Location: Phoenix AZ, Tucson AZ, Murrieta CA, Orange CA,
Sponsor: Ferring Pharmaceuticals
Sex: All
Age: 18+
Code: NCT06510374
Phase3, Recruiting
Low Sodium Oxybate in Patients With Idiopathic Hypersomnia
for
Idiopathic Hypersomnia
Location: Phoenix AZ, Redwood City CA, Jacksonville FL, Boston MA
Sponsor: Mayo Clinic
Sex: All
Age: 18 - 65
Code: NCT05837091
Recruiting
Dual BET and CBP/p300 Inhibitor in Patients With Targeted Advanced Solid Tumors and Hematological Malignancies
Location: Phoenix AZ, Houston TX, Seattle WA, Rochester MN,
Sponsor: Epigenetix, Inc.
Sex: All
Age: 18+
Code: NCT05488548
Phase1, Recruiting
Leveraging Methylated DNA Markers (MDMs) in the Detection of Endometrial Cancer, Ovarian Cancer, and Cervical Cancer
for
Endometrial Cancer, Cervical Cancer,
Location: Phoenix AZ, Katy TX, Houston TX, Jackson MS,
Sponsor: Mayo Clinic
Sex: Female
Age: 18+
Code: NCT05051722
Recruiting
Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy
for
Prostate Cancer, Prostatic Neoplasms
Location: Phoenix AZ, Orange CA, Los Angeles CA, Murray UT,
Sponsor: Clarity Pharmaceuticals Ltd
Sex: Male
Age: 18+
Code: NCT06056830
Phase3, Recruiting
A Phase 1, First in Human Study of TORL-4-500 in Patients With Advanced Cancer
for
Advanced Solid Tumor, Hepatocellular Carcinoma
Location: Phoenix AZ, Fullerton CA, Torrance CA, Los Angeles CA,
Sponsor: TORL Biotherapeutics, LLC
Sex: All
Age: 18+
Code: NCT06005740
Phase1, Recruiting
Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma
for
Relapsed or Refractory Multiple Myeloma
Location: Phoenix AZ, Orange CA, Rochester MN, Nashville TN,
Sponsor: Jiangsu Simcere Pharmaceutical Co., Ltd.
Sex: All
Age: 18+
Code: NCT06375044
Phase1, Recruiting
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer
for
Metastatic HER2-positive Breast Cancer
Location: Phoenix AZ, Tucson AZ, Cerritos CA, Los Angeles CA,
Sponsor: Jazz Pharmaceuticals
Sex: All
Age: 18+
Code: NCT06435429
Phase3, Recruiting
A Study to Investigate Safety and Effectiveness of Tacabrutideg (BGB-16673) in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies